$ News

Pfizer Gets Metsera: Why The $20.65 CVR Is Highly Likely To Pay Out (In Part)

Wall Street Brunch: Here Come The 13Fs

Update: Metsera Gets 'Superior' Acquisition Bid From Novo Nordisk, Challenging Pfizer Merger

Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion

Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

Novo, Pfizer Boost Metsera Bids in Obesity Startup Battle

Pfizer raises and narrows full-year earnings guidance

Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance

Metsera (MTSR) Jumps 20% as Big Pharma Battle Heats Up Over Takeover

Market Chatter: Pfizer Could Use White House Connections to Counter Novo Nordisk's Bid for Metsera

Novo is no longer suppressing its M&A appetite

Assessing Metsera (MTSR) Valuation After Recent Share Price Surge

Metsera (MTSR): Evaluating Valuation After a 48% One-Month Share Price Surge

Should You Buy Pfizer (PFE) Before a Breakout Begins?

Pfizer: Mastering The Art Of The Deal With Metsera - Upgraded To Buy

Pfizer to Cut Drug Prices Under Deal With Trump Administration; Plans $70 Billion US Investment

Bank of America Securities Maintains a Neutral Stance on Pfizer Inc. (PFE)

Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

Metsera (MTSR): Rethinking Valuation After a Quiet 49% Rally

Pfizer: Invest For The Yield, Not The Weight-Loss Drug Chase